Rajesh Parekh - Galapagos Non-Executive Chairman of the Board
GLPGF Stock | USD 35.52 0.00 0.00% |
Chairman
Dr. Rajesh B. Parekh was NonExecutive Chairman of the Board of Galapagos NV since July 2004. He is also Chairman of the Company Nomination and Remuneration Committee. He is a General Partner at Advent Life Sciences LLP, which he joined in 2006. During an academic career at Oxford University, he cofounded Oxford GlycoSciences PLC, where he served as Chief Scientific Officer and Chief Executive Officer from 1988 until its sale to Celltech Group PLC in 2003. He has founded or served on the boards of several life sciences companies in the United States and Europe including Celldex Therapeutics, Inc. Avila Therapeutics, Inc. EUSA Pharma Limited Thiakis Limited and Amsterdam Molecular Therapeutics Holding N.V. . Dr. Parekh currently serves as a member of the board of directors of Advent Venture Partners Advent Life Sciences LLP Aleta Inc. Arrakis, Inc. Aura Inc. Artax Inc. Capella BioSciences Ltd. Cellnovo Limited EnCipher Limited Itara Limited Levicept Limited Macrolide Pharmaceuticals, Inc. PE Limited and Project Paradise Limited. He is also a member of the supervisory board of the Novartis Venture Fund. During the past five years, he served as a member of the board of directors of Biocartis NV, 4Antibody AG, NeRRe Therapeutics Limited, F2G Limited, LuxFold S.A., CoCo Therapeutics Limited. He received his MA in Biochemistry and DPhil in Molecular Medicine from the University of Oxford, where he was a Senior Research Fellow and Professor. since 2004.
Age | 57 |
Tenure | 20 years |
Phone | 32 1 534 29 00 |
Web | https://www.glpg.com |
Galapagos Management Efficiency
The company has return on total asset (ROA) of (0.0119) % which means that it has lost $0.0119 on every $100 spent on assets. This is way below average. Galapagos' management efficiency ratios could be used to measure how well Galapagos manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 12 records | CHAIRMAN Age | ||
Jeffrey Leiden | Vertex Pharmaceuticals | 62 | |
Roy Vagelos | Regeneron Pharmaceuticals | 88 | |
Joshua Boger | Vertex Pharmaceuticals | 63 | |
Jeppe Christiansen | Novo Nordisk AS | 61 | |
Uli Hacksell | Moderna | 67 | |
Helge Lund | Novo Nordisk AS | 58 | |
Rodney McMullen | Kroger Company | 55 | |
Goran Ando | Novo Nordisk AS | 67 | |
Vuong Trieu | Moderna | 50 | |
Michael French | Moderna | 54 | |
William McMullen | Kroger Company | 63 | |
Jeffrey MD | Vertex Pharmaceuticals | 68 |
Management Performance
Return On Equity | 0.0021 | |||
Return On Asset | -0.0119 |
Galapagos NV Leadership Team
Elected by the shareholders, the Galapagos' board of directors comprises two types of representatives: Galapagos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galapagos. The board's role is to monitor Galapagos' management team and ensure that shareholders' interests are well served. Galapagos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galapagos' outside directors are responsible for providing unbiased perspectives on the board's policies.
Rajesh Parekh, Non-Executive Chairman of the Board | ||
Andre Hoekema, Sr. VP of Corporate Devel. | ||
Katrine Bosley, Independent Non-Executive Director | ||
John Montana, Managing Argenta | ||
Walid AbiSaab, Member of the Executive Committee, Chief Medical Officer | ||
Marieke Vermeersch, Head Communication | ||
Howard Rowe, Non-Executive Independent Director | ||
Bob Rajan, Non-Executive Independent Director | ||
Harrold Barlingen, Non-Executive Director | ||
Raj Parekh, Non-Executive Chairman of the Board | ||
Elizabeth Goodwin, VP Corporate Communications & Investor Relations | ||
Mary Kerr, Non-Executive Independent Director | ||
Michele MBA, Chief Board | ||
Piet Wigerinck, Chief Scientific Officer | ||
Chantal Tasset, Head Devel | ||
Sofie Gijsel, Head Relations | ||
MBA MBA, COO Pres | ||
Bart Filius, CFO | ||
Christine Mummery, Non-Executive Independent Director | ||
Werner Cautreels, Non-Executive Independent Director | ||
Onno Stolpe, Co-Founder, CEO, Managing Director and Executive Director |
Galapagos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Galapagos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0021 | |||
Return On Asset | -0.0119 | |||
Profit Margin | 0.01 % | |||
Operating Margin | (0.17) % | |||
Current Valuation | (2.11 B) | |||
Shares Outstanding | 65.84 M | |||
Shares Owned By Insiders | 26.24 % | |||
Shares Owned By Institutions | 32.13 % | |||
Price To Earning | 454.11 X | |||
Price To Book | 0.92 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galapagos NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Galapagos NV information on this page should be used as a complementary analysis to other Galapagos' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Galapagos Pink Sheet analysis
When running Galapagos' price analysis, check to measure Galapagos' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galapagos is operating at the current time. Most of Galapagos' value examination focuses on studying past and present price action to predict the probability of Galapagos' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galapagos' price. Additionally, you may evaluate how the addition of Galapagos to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Bonds Directory Find actively traded corporate debentures issued by US companies |